Skip to main content
BCDA
NASDAQ Life Sciences

BioCardia Reports Negative Equity, Short Cash Runway, and Ongoing Delisting Risk

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$1.1
Mkt Cap
$11.925M
52W Low
$1
52W High
$2.92
Market data snapshot near publication time

summarizeSummary

BioCardia's Q1 2026 report reveals a critical financial state with negative stockholders' equity, a cash runway only until June 2026, and continued Nasdaq delisting risk, despite ongoing ATM sales and positive clinical updates.


check_boxKey Events

  • Critical Liquidity Issues

    Cash and cash equivalents stood at $951,000 as of March 31, 2026, which management believes is insufficient to fund planned expenditures beyond June 2026.

  • Negative Stockholders' Equity

    Total stockholders' equity declined to a deficit of $(1,066,000) as of March 31, 2026, from $895,000 on December 31, 2025.

  • Ongoing Nasdaq Delisting Risk

    The company remains non-compliant with Nasdaq's minimum stockholders' equity requirement, with a plan to regain compliance due by May 25, 2026.

  • Continued At-The-Market (ATM) Sales

    Between April 1 and May 14, 2026, the company sold an additional 434,352 shares for $536,000 in gross proceeds, with approximately $4.5 million remaining under the ATM program.


auto_awesomeAnalysis

BioCardia's first-quarter report highlights a critical financial situation, with cash and cash equivalents of only $951,000 as of March 31, 2026, which management states is insufficient to fund operations beyond June 2026. The company's total stockholders' equity has deteriorated further into a deficit of $(1,066,000), down from a positive balance at year-end. This negative equity position directly contributes to the ongoing Nasdaq delisting risk, for which the company must submit a compliance plan by May 25, 2026. While the company continues to raise capital through its At-The-Market (ATM) offering, having sold an additional $536,000 in shares since quarter-end, these dilutive measures are a temporary solution to severe liquidity challenges. The positive clinical and regulatory updates, including favorable FDA and PMDA feedback, are significant for the long-term pipeline but are overshadowed by the immediate and pressing financial distress.

At the time of this filing, BCDA was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $1.00 to $2.92. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BCDA - Latest Insights

BCDA
May 15, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
BCDA
May 15, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
9
BCDA
May 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
BCDA
Apr 28, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
BCDA
Apr 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
BCDA
Apr 15, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
BCDA
Apr 15, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
BCDA
Apr 02, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
BCDA
Mar 24, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
BCDA
Mar 17, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8